Nasdaq:ALGS
Aligos Therapeutics, Inc.
A pre-revenue biopharmaceutical firm utilizing CRISPR-based gene editing to pioneer curative therapies for rare genetic disorders.
Key Metrics
Investment Thesis
Bull Case
Bull investors are attracted to Aligos for its potential to deliver a blockbuster orphan drug once clinical data validates its gene editing platform in late-stage trials. The recent cash flow from financing of $101.6M provides a runway that could allow the company to reach commercial launch without immediate dilution, assuming successful patient recruitment and trial completion.
Bear Case
Bear investors cite the persistent negative operating cash flow of $-82.5M and a massive retained earnings deficit of $-642.2M as signs of a financially precarious business model that requires constant capital injections. With revenue declining year-over-year and no commercial products on the market yet, the stock carries extreme binary risk where total value could vanish if key clinical endpoints are missed.
About Aligos Therapeutics, Inc.
Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare genetic diseases, including Duchenne muscular dystrophy and spinal muscular atrophy. The company operates in the specialized orphan drug market, leveraging its proprietary gene editing technology to create first-in-class treatments for patients with limited therapeutic options.
Analysis
Management Discussion
Management successfully reduced net losses significantly from a high-water mark of $-131.2M in 2024 to $-24.2M in 2025, likely due to cost optimization and the realization of major financing proceeds totaling over $100M. However, revenue contraction from $6.2M in 2023 to $2.2M in 2025 suggests that milestone payments may have been exhausted or delayed, while research and development expenses remain elevated at $69.5M.
Industry Overview
The biotechnology industry for rare diseases is characterized by high R&D costs, long development timelines, and significant regulatory hurdles before a product can be approved by agencies like the FDA. Success in this sector often hinges on securing large-scale partnerships with major pharmaceutical companies to share financial risk and gain market access.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $6.2M | $3.6M | $2.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $6.2M | $3.6M | $2.2M |
| Operating Expenses | $97.6M | $94.3M | $92.8M | $90.2M |
| Operating Income | $-97.6M | $-88.1M | $-89.2M | $-88.0M |
| R&D | $85.1M | $73.0M | $70.3M | $69.5M |
| G&A | $26.4M | $30.6M | $22.8M | $20.7M |
| Stock-Based Comp | $14.7M | $12.7M | $8.5M | $5.0M |
| Depreciation | $2.3M | $1.6M | $1.0M | $930.0K |
| Other OpEx | $-13.9M | $-9.3M | $-334.0K | $0 |
| Non-Operating Income | $1.6M | $1.2M | $-41.7M | $64.1M |
| Pre-Tax Income | $-95.9M | $-86.9M | $-130.9M | $-23.9M |
| Income Tax | $106.0K | $795.0K | $331.0K | $314.0K |
| Continuing Ops | $-96.0M | $-87.7M | $-131.2M | $-24.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-96.0M | $-87.7M | $-131.2M | $-24.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-96.0M | $-87.7M | $-131.2M | $-24.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $133.5M | $141.1M | $62.1M | $82.9M |
| Cash & Equivalents | $81.3M | $135.7M | $37.0M | $18.3M |
| Marketable Securities | $44.5M | — | $19.9M | $59.5M |
| Other Current Assets | $7.7M | $5.4M | $5.2M | $5.0M |
| Long-Term Assets | $13.1M | $10.4M | $8.0M | $5.7M |
| PP&E (Net) | $4.8M | $3.3M | $2.4M | $1.9M |
| Operating Leases | $7.7M | $6.6M | $5.0M | $3.1M |
| Other LT Assets | $634.0K | $625.0K | $627.0K | $715.0K |
| Total Assets | $146.7M | $151.5M | $70.1M | $88.5M |
| Current Liabilities | $33.1M | $23.9M | $21.7M | $21.2M |
| Accounts Payable | $4.7M | $2.5M | $2.6M | $4.0M |
| Current Leases | $3.0M | $3.2M | $3.4M | $3.6M |
| Other Current Liab | $9.3M | $1.3M | $187.0K | $145.0K |
| Long-Term Liabilities | $9.7M | $35.5M | $77.3M | $13.8M |
| LT Operating Leases | $9.2M | $7.7M | $4.8M | $1.5M |
| Other LT Liab | $463.0K | $27.9M | $72.5M | $12.2M |
| Total Liabilities | $42.8M | $59.4M | $99.1M | $35.0M |
| Shareholders' Equity | $103.9M | $92.1M | $-29.0M | $53.5M |
| Retained Earnings | $-399.1M | $-486.8M | $-618.0M | $-642.2M |
| AOCI | $401.0K | $545.0K | $451.0K | $468.0K |
| Total L&E | $146.7M | $151.5M | $70.1M | $88.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-96.0M | $-87.7M | $-131.2M | $-24.2M |
| Non-Cash Adjustments | $27.3M | $20.4M | $53.2M | $-57.4M |
| Working Capital Changes | $-10.6M | $-11.7M | $-2.7M | $-867.0K |
| Cash from Operations | $-79.4M | $-79.0M | $-80.7M | $-82.5M |
| Capital Expenditures | $943.0K | $19.0K | $130.0K | — |
| Cash from Investing | $-26.3M | $45.0M | $-18.3M | $-37.8M |
| Cash from Financing | $164.0K | $88.3M | $355.0K | $101.6M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-105.5M | $54.3M | $-98.7M | $-18.7M |
| Beginning Cash | $187.0M | $81.5M | $135.8M | $37.1M |
| Ending Cash | $81.5M | $135.8M | $37.1M | $18.4M |
Frequently Asked Questions
How does Aligos Therapeutics, Inc. make money?
The company's revenue is primarily derived from licensing agreements and collaborations, such as the partnership with Pfizer for DMD programs. Revenue streams are heavily dependent on upfront payments, milestone triggers upon clinical success, and royalty arrangements rather than direct product sales, given its current pre-commercialization status.
What are the main risks for ALGS?
The company faces substantial risk from ongoing cash burn, having posted a net loss of $24.2M in 2025 with limited cash reserves remaining despite recent financing activity. As a pre-revenue entity, Aligos is highly sensitive to the failure of clinical trials for its pipeline assets, which could lead to immediate delisting or bankruptcy if milestones are not met. The biotechnology sector is volatile, and the company relies heavily on equity financing to fund operations, diluting existing shareholders in each round of capital raises.
What is ALGS's competitive advantage?
Aligos possesses a proprietary CRISPR/Cas9 platform that offers high specificity and efficiency in editing human genes, providing a significant technical moat against competitors. The company holds extensive intellectual property protection across multiple indications, including Duchenne muscular dystrophy, spinal muscular atrophy, and cystic fibrosis, creating strong barriers to entry for generic or competitor therapies.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.